XTalks

FEBRUARY 21, 2024

Recently, Eli Lilly revealed promising results from a mid-stage trial, indicating that its popular drug, tirzepatide (marketed as Zepbound and Mounjaro for weight loss and diabetes, respectively), may be an effective treatment for the fatty liver disease metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). Lilly is also looking to pitch Mounjaro as an obesity drug and directly take on Novo’s Wegovy.

Sales 98

Sales FDA Approval Production Insulin 98

Pharmaceutical Technology

DECEMBER 22, 2022

AstraZeneca and Daiichi Sankyo win the Business Expansion award this year as their collaboration bears more fruit in terms of new approvals. The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth.

Insulin 130

Insulin Production Development Genetics 130

XTalks

OCTOBER 11, 2023

While the link between GLP-1 inhibitors and gastrointestinal side effects has been known for diabetics taking the drugs, this is the first study that was conducted among non-diabetics taking them for weight loss. Rybelsus is Novo’s third semaglutide product on the market, a tablet form of the drug used for the treatment of type 2 diabetes.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

XTalks

JULY 3, 2023

Making for another landmark cell and gene therapy approval this month, the US Food and Drug Administration (FDA) has signed off on CellTrans’ Lantidra (donislecel), the first cell therapy for type 1 diabetes. Lantidra is thought to increase insulin secretion through the infusion of allogeneic insulin-producing islet beta cells.

Insulin 98

Insulin Gene Therapy Gene Regulation 98

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

SEPTEMBER 17, 2020

Surrogate endpoints were used as the basis for approval of 45 percent of new drugs reviewed by the FDA between 2010 and 2012. In the case of the former, pharmaceutical and biologics companies would be eligible for approval of their product through traditional regulatory pathways; the latter could support accelerated approval.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. Pfizer’s total global revenue in 2022 from Comirnaty was $37.81

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

AUGUST 17, 2020

Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. There is therefore a breadth of opportunity with this drug says Dr. Suri.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

FEBRUARY 2, 2023

Amgen’s Amjevita, the first biosimilar version of AbbVie’s blockbuster arthritis injection Humira (adalimumab), has finally hit the market this week after fetching US Food and Drug Administration (FDA) approval back in 2016. Alvotech’s biosimilar is pending FDA approval. Amjevita Launch: Cost Savings, But for Whom?

Marketing 52

Marketing FDA Approval Branding Drugs 52

XTalks

JUNE 12, 2023

The US Food and Drug Administration (FDA) granted approval to four of Medtronic’s cardiovascular product offerings, further expanding the company’s foothold in this sector. Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. It also plans to launch these products in the US.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

MAY 20, 2022

Eli Lilly’s diabetes and weight loss shot tirzepatide, known by its trade name Mounjaro, received a much-anticipated nod from the US Food and Drug Administration (FDA) last week for the treatment of diabetes. Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9

Insulin 52

Insulin Life Science Drugs Sales 52

XTalks

FEBRUARY 14, 2024

Nonetheless, the hearing did highlight important facts and problems about drug pricing in the US, putting the pharma CEOs in the hot seat. Sanders pointed out GoFundMe pages that patients had to set up to try to afford expensive drugs. Melissa Barber who has estimated that it costs just $18 to manufacture a year’s supply of the drug.

Drugs 52

Drugs Insulin Pharmacy Development 52